Protective effects of psoralen polymer lipid nanoparticles on doxorubicin - induced myocardial toxicity

Detalhes bibliográficos
Autor(a) principal: Meng, Fansu
Data de Publicação: 2022
Outros Autores: Ouyang, Yong, Ma, Qianqian, Du, Manling, Liu, Hui, Zhuang, Yong, Pang, Mujuan, Cai, Tiange, Cai, Yu
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/205062
Resumo: Doxorubicin (DOX) induced myocardial toxicity may limit its therapeutic use in clinic. Psoralen (PSO), a major active tricyclic furocoumarin extracted from Psoralea corylifolia, is widely used as an antineoplastic agent in treatment of leukemia and other cancers. This study is aim to find the protective effect of psoralen polymer lipid nanoparticles (PSO-PLN) on doxorubicin-induced myocardial toxicity in mice. The model of myocardial toxicity induced by DOX was established. The experiment was divided into 6 groups: normal saline group, DOX + Sulfotanshinone Sodium, DOX + PSO-PLN (3 mg/kg), DOX + PSO-PLN (6 mg/kg), DOX + PSO-PLN (9 mg/ kg), DOX group. DOX alone treated mice lead to a significant decrease in the body weight, heart weight, and increase in the serum levels of lactate dehydrogenase (LDH), creatine kinase (CK) and malondialdehyde (MDA) markers of cardiotoxicity. However, DOX reduced glutathione (GSH) content and activities of antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GPX), were recovered by PSO-PLN. And PSO-PLN also decreased markers of cardiotoxicity in the serum. Western blotting data showed that the protective effects of PSO-PLN might be mediated via regulation of protein kinase A (PKA) and p38. Our study suggest that PSO-PLN possesses antioxidant activities, inactivating PKA and p38 effect, which in turn protect the heart from the DOX-induced cardiotoxicity.
id USP-31_fe7024c5f516c339f00601ee94e7c53e
oai_identifier_str oai:revistas.usp.br:article/205062
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Protective effects of psoralen polymer lipid nanoparticles on doxorubicin - induced myocardial toxicityDoxorubicinCadiotoxicityPsoralenPsoralen polymer lipid nanoparticlesAntioxidantDoxorubicin (DOX) induced myocardial toxicity may limit its therapeutic use in clinic. Psoralen (PSO), a major active tricyclic furocoumarin extracted from Psoralea corylifolia, is widely used as an antineoplastic agent in treatment of leukemia and other cancers. This study is aim to find the protective effect of psoralen polymer lipid nanoparticles (PSO-PLN) on doxorubicin-induced myocardial toxicity in mice. The model of myocardial toxicity induced by DOX was established. The experiment was divided into 6 groups: normal saline group, DOX + Sulfotanshinone Sodium, DOX + PSO-PLN (3 mg/kg), DOX + PSO-PLN (6 mg/kg), DOX + PSO-PLN (9 mg/ kg), DOX group. DOX alone treated mice lead to a significant decrease in the body weight, heart weight, and increase in the serum levels of lactate dehydrogenase (LDH), creatine kinase (CK) and malondialdehyde (MDA) markers of cardiotoxicity. However, DOX reduced glutathione (GSH) content and activities of antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GPX), were recovered by PSO-PLN. And PSO-PLN also decreased markers of cardiotoxicity in the serum. Western blotting data showed that the protective effects of PSO-PLN might be mediated via regulation of protein kinase A (PKA) and p38. Our study suggest that PSO-PLN possesses antioxidant activities, inactivating PKA and p38 effect, which in turn protect the heart from the DOX-induced cardiotoxicity.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2022-12-19info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/20506210.1590/s2175-97902022e19245Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/205062/194498Copyright (c) 2022 Brazilian Journal of Pharmaceutical Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMeng, FansuOuyang, YongMa, QianqianDu, ManlingLiu, HuiZhuang, YongPang, MujuanCai, TiangeCai, Yu2023-05-26T13:00:30Zoai:revistas.usp.br:article/205062Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2023-05-26T13:00:30Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Protective effects of psoralen polymer lipid nanoparticles on doxorubicin - induced myocardial toxicity
title Protective effects of psoralen polymer lipid nanoparticles on doxorubicin - induced myocardial toxicity
spellingShingle Protective effects of psoralen polymer lipid nanoparticles on doxorubicin - induced myocardial toxicity
Meng, Fansu
Doxorubicin
Cadiotoxicity
Psoralen
Psoralen polymer lipid nanoparticles
Antioxidant
title_short Protective effects of psoralen polymer lipid nanoparticles on doxorubicin - induced myocardial toxicity
title_full Protective effects of psoralen polymer lipid nanoparticles on doxorubicin - induced myocardial toxicity
title_fullStr Protective effects of psoralen polymer lipid nanoparticles on doxorubicin - induced myocardial toxicity
title_full_unstemmed Protective effects of psoralen polymer lipid nanoparticles on doxorubicin - induced myocardial toxicity
title_sort Protective effects of psoralen polymer lipid nanoparticles on doxorubicin - induced myocardial toxicity
author Meng, Fansu
author_facet Meng, Fansu
Ouyang, Yong
Ma, Qianqian
Du, Manling
Liu, Hui
Zhuang, Yong
Pang, Mujuan
Cai, Tiange
Cai, Yu
author_role author
author2 Ouyang, Yong
Ma, Qianqian
Du, Manling
Liu, Hui
Zhuang, Yong
Pang, Mujuan
Cai, Tiange
Cai, Yu
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Meng, Fansu
Ouyang, Yong
Ma, Qianqian
Du, Manling
Liu, Hui
Zhuang, Yong
Pang, Mujuan
Cai, Tiange
Cai, Yu
dc.subject.por.fl_str_mv Doxorubicin
Cadiotoxicity
Psoralen
Psoralen polymer lipid nanoparticles
Antioxidant
topic Doxorubicin
Cadiotoxicity
Psoralen
Psoralen polymer lipid nanoparticles
Antioxidant
description Doxorubicin (DOX) induced myocardial toxicity may limit its therapeutic use in clinic. Psoralen (PSO), a major active tricyclic furocoumarin extracted from Psoralea corylifolia, is widely used as an antineoplastic agent in treatment of leukemia and other cancers. This study is aim to find the protective effect of psoralen polymer lipid nanoparticles (PSO-PLN) on doxorubicin-induced myocardial toxicity in mice. The model of myocardial toxicity induced by DOX was established. The experiment was divided into 6 groups: normal saline group, DOX + Sulfotanshinone Sodium, DOX + PSO-PLN (3 mg/kg), DOX + PSO-PLN (6 mg/kg), DOX + PSO-PLN (9 mg/ kg), DOX group. DOX alone treated mice lead to a significant decrease in the body weight, heart weight, and increase in the serum levels of lactate dehydrogenase (LDH), creatine kinase (CK) and malondialdehyde (MDA) markers of cardiotoxicity. However, DOX reduced glutathione (GSH) content and activities of antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GPX), were recovered by PSO-PLN. And PSO-PLN also decreased markers of cardiotoxicity in the serum. Western blotting data showed that the protective effects of PSO-PLN might be mediated via regulation of protein kinase A (PKA) and p38. Our study suggest that PSO-PLN possesses antioxidant activities, inactivating PKA and p38 effect, which in turn protect the heart from the DOX-induced cardiotoxicity.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-19
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/205062
10.1590/s2175-97902022e19245
url https://www.revistas.usp.br/bjps/article/view/205062
identifier_str_mv 10.1590/s2175-97902022e19245
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/205062/194498
dc.rights.driver.fl_str_mv Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)
Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022)
Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222916522016768